PMC:7696151 / 105142-105624
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
4028 | 255-258 | Gene | denotes | CD4 | Gene:920 |
4037 | 350-353 | Gene | denotes | CD8 | Gene:925 |
4046 | 76-84 | Species | denotes | patients | Tax:9606 |
4120 | 86-89 | Chemical | denotes | HCQ | MESH:D006886 |
4121 | 101-112 | Chemical | denotes | hydroxyurea | MESH:D006918 |
4122 | 124-134 | Chemical | denotes | didanosine | MESH:D016049 |
4168 | 61-75 | Disease | denotes | HIV-1 infected | MESH:D015658 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T717 | 0-482 | Sentence | denotes | Paton, et al. (2005) [20] open-label, noncomparative stud17 HIV-1 infected patients HCQ (200 mg) + hydroxyurea (500 mg) + didanosine (125–200 mg), taken twice daily.144 weeks Mean viral load was reduced by 1.6 log10 copies/mL below baseline (p = 0.001)CD4+ cell counts were significantly increased by a mean of 3.3 ± 6.9%, p = 0.095 at 144th week.CD8 cells percentage was reduced by 11.5 ± 14% per 48th week (p = 0.005) and remained around 10% until the 144th week Not reported. |